Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Interferon Beta
 More »

  • Pfenex and Agila Biotech Target Biosimilars
    The lead product for the joint venture is Interferon beta-1b, a biosimilar to Betaseron®, indicated for relapsing-remitting and secondary-progressive forms of multiple sclerosis. ...
    4-16-2013
  • Top 10 Clinical Trial Failures of 2012
    plus interferon-alfa-2a, or IFN-alpha-2a in INTORACT Phase III trial (B1771006). ... Alzheimer's disease Type of drug: Amyloid beta (Aß) antibody How it failed: Did not meet ...
    2-1-2013
  • Bittersweet News at Biogen Idec
    Its Q4 2012 revenues increased 10% year-over-year to about $295.2 million from $269.4 million a year earlier. Biogen Idec co-markets Tysabri with Elan. Avonex (interferon beta-1a) ...
    1-28-2013
  • Epigenetics: Promising Field Delivers
    ... lab illustrated the strength of this strategy with two inducible enhancers, a synthetic cAMP-regulated enhancer, and a virus-inducible enhancer of the human interferon beta gene. ...
    1-15-2013
  • Nuron, Raptor in Royalty Deals
    They include its most advanced drug candidate NU100, a human interferon beta-1b now in a Phase III trial for multiple sclerosis, enrollment for which was completed last month; and ...
    12-20-2012
  • Nurturing Protein Therapeutics to Next Level
    ReCODE improves on first-generation protein therapeutics, such as growth hormone, interferon-alpha, and interferon-beta, Dr. Cho remarks. These proteins are composed of only the 20 ...
    11-15-2012
  • Needle-Free Anthrax Vaccine Wins NIAID Contract
    The Pfenex in-house and partnered pipeline includes biosimilars of ranibizumab, interferon beta 1b, human growth hormone, and granulocyte colony-stimulating factors, along with the ...
    10-17-2012
  • Funds Awarded for MS Drug Clinical Trial
    cholesterol-like compound olesoxime therapy in combination with including beta interferon in 30 relapsing-remitting MS patients who are stably treated using beta interferon 1a. ...
    10-11-2012
  • Regulus, Biogen Idec Partner on MS Biomarkers
    Tysabri® (natalizumab) achieved revenue of $280 million, in the second quarter of this year, while Avonex(tm) (interferon beta-1a) achieved revenues of $762 million. The firm's ...
    8-16-2012
  • InterMune Sells Actimmune to Vidara for $55M
    InterMune is selling its synthetic gamma interferon-1b drug, Actimmune, to specialty ... Lead drug Esbriet is a small molecule TGF-beta inhibitor approved in Europe for the ...
    5-22-2012
  • Latest Guideline Summary Document Solidifies EMA as Front Runner...
    ... It progressed from recombinant human insulin to larger molecules including recombinant erythropoietins, mAbs, recombinant interferon beta, recombinant follicle stimulation hormone, ...
    5-10-2012
  • Merck KGaA Sitting Out M&A Dance to Focus Instead on Cuts, Pipeline
    ... Sanford C. Bernstein, told Bloomberg that Merck KGaA faced an additional pipeline challenge of growing competition for its MS drug Rebif (Interferon beta-1a) from newer treatments. ...
    4-20-2012
  • Nuron Gains Preclinical Alzheimer Vaccine from Vitruvian BioMedical
    Nuron's lead candidate is an interferon beta product for multiple sclerosis (MS). The company does have one vaccine in its portfolio; it acquired HibTiter® from Wyeth, a wholly ...
    4-9-2012
  • Report Cautions More Drugs, Diagnostics Needed in Europe for...
    Frost & Sullivan's report comes two months after the EMA released a draft guidance on January 23 covering clinical and nonclinical requirements for developing interferon beta ...
    3-14-2012
  • Poll Shows Most Are Dissatisfied with U.S. Progress on Biosimilars
    The EMA has slowly but surely developed guidelines for different types of biosimilars; most recently, it began soliciting formal comment last month on interferon beta biosimilars. ...
    2-21-2012
  • More »

    Journal Articles

  • Human Amniotic Fluid-Derived Mesenchymal Stem Cells As Therapeutic...
    Vasiliki Bitsika, Maria G. Roubelakis, Dimitra Zagoura, Ourania Trohatou, Manousos Makridakis, Kalliopi I. Pappa, Frank C. Marini, Antonia Vlahou, Nicholas P. Anagnou
    Stem Cells and Development
    The main characteristic of AF-MSCs is their efficient and rapid expansion in vitro. Herein, we investigated the AF-MSCs tropism and capability to transport interferon beta (IFNß) ...
  • Soluble Factors-Mediated Immunomodulatory Effects of Canine Adipose...
    Jung Won Kang, Kyung-Sun Kang, Hye Cheong Koo, Jeong Ran Park, Eun Wha Choi, Yong Ho Park
    Stem Cells and Development
    the mRNA of transforming growth factor beta (TGF-ß), IL-6, IL-8, CCL2, CCL5, vascular ... Moreover, TNF-a production significantly decreased, whereas TGF-ß, IL-6, and interferon-? ...
  • Markers of Progenitor Cell Recruitment and Differentiation Rise...
    Atman P. Shah, Scott T. Youngquist, Christian D. McClung, Ekaterina Tzvetkova, Mohammed A. Hanif, John P. Rosborough, James T. Niemann
    Journal of Interferon & Cytokine Research
    Journal of Interferon & Cytokine Research Clinical administration of bone marrow-derived ... Thymosin beta-4 (TB4) and vascular endothelial growth factor (VEGF) are linked to adult ...
  • An Assessment of Biological Potency and Molecular Characteristics...
    Anthony Meager, Carl Dolman, Paula Dilger, Chris Bird, Gavin Giovannoni, Huub Schellekens, Robin Thorpe, Meenu Wadhwa
    Journal of Interferon & Cytokine Research
    An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products Journal of Interferon & Cytokine Research ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll